News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

News|Videos|May 20, 2023

Looking Toward the Future of American Psychiatry

Author(s)Petros Levounis, MD, MA

Petros Levounis, MD, MA, reflects on his upcoming presidency for the American Psychiatric Association.

CONFERENCE REPORTER
The American Psychiatric Association (APA) President Elect, Petros Levounis, MD, MA, dicusses his roadmap for the future of psychiatry, with a focus on addiction, specifically vaping, opioids, alcohol, and internet addictions.

Dr Levounis is Presiddent Elect of the APA; professor and chair of the Department of Psychiatry at Rutgers New Jersey Medical School; chief of service at University Hospital in Newark, New Jersey; and the author of 13+ books.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

What Does Interventional Psychiatry Actually Mean? Reframing Non-Standard Treatments for Depression

What Does Interventional Psychiatry Actually Mean? Reframing Non-Standard Treatments for Depression

ByLara Shirikjian, MD

July 31st 2026

Gus Alva, MD, on Agitation, Psychosis, and Cognition in Alzheimer Disease

Gus Alva, MD, on Agitation, Psychosis, and Cognition in Alzheimer Disease

ByGustavo Alva, MD, DFAPA

July 31st 2026

TensorSpark/Adobe Stock

Psyched Perspectives: Substance Use Awareness, A Conversation on Advocacy & Intervention

ByFrank A. Clark, MD,Chelby Drafts

July 31st 2026

Virtual Gambling Disorder Treatment Shows Rapid Symptom Improvement in New Study

Virtual Gambling Disorder Treatment Shows Rapid Symptom Improvement in New Study

ByPatrick Campbell

July 31st 2026

schizophrenia

Real-World and Long-Term Trial Data Show Xanomeline/Trospium Cuts Hospitalizations, Antipsychotic Burden in Schizophrenia

ByPsychiatric Times Editors

July 30th 2026

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Trending on Psychiatric Times

FAQ: What Clinicians Need to Know About Postpartum Psychosis

FDA Approves Oveporexton for Narcolepsy Type 1, First Drug to Treat Full Range of NT1 Symptoms

Xanomeline/Trospium in Treatment-Refractory Bipolar I Disorder With Psychosis: A Case Report of Rapid Agitation Control and Functional Improvement

How Wearable Tech Can Translate Into Practical Precision Medicine in Psychiatry

Bringing Wearable Data Into Psychiatric Care: Amae Health Partners With Google Health Enterprise to Improve Outcomes